142 related articles for article (PubMed ID: 22814292)
1. Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin.
Kurimoto M; Matsuoka H; Hanaoka N; Uneda S; Murayama T; Sonoki T; Nakakuma H
Leukemia; 2013 Jan; 27(1):233-5. PubMed ID: 22814292
[No Abstract] [Full Text] [Related]
2. A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia.
Medeiros BC; Tanaka TN; Balaian L; Bashey A; Guzdar A; Li H; Messer K; Ball ED
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):346-352.e5. PubMed ID: 29572158
[TBL] [Abstract][Full Text] [Related]
3. Gemtuzumab Ozogamicin Containing Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia (AML) in Children.
Liu AP; Leung AW; Cheuk DK; Lee V; Ha SY
J Pediatr Hematol Oncol; 2018 Mar; 40(2):163-168. PubMed ID: 29240026
[No Abstract] [Full Text] [Related]
4. Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia.
Chowdhury S; Seropian S; Marks PW
Am J Hematol; 2009 Sep; 84(9):599-600. PubMed ID: 19650144
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Daver N; Kantarjian H; Ravandi F; Estey E; Wang X; Garcia-Manero G; Jabbour E; Konopleva M; O'Brien S; Verstovsek S; Kadia T; Dinardo C; Pierce S; Huang X; Pemmaraju N; Diaz-Pines-Mateo M; Cortes J; Borthakur G
Leukemia; 2016 Feb; 30(2):268-73. PubMed ID: 26365212
[TBL] [Abstract][Full Text] [Related]
6. High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.
Stone RM; Moser B; Sanford B; Schulman P; Kolitz JE; Allen S; Stock W; Galinsky I; Vij R; Marcucci G; Hurd D; Larson RA;
Leuk Res; 2011 Mar; 35(3):329-33. PubMed ID: 20688393
[TBL] [Abstract][Full Text] [Related]
7. Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia.
Oshikawa G; Kakihana K; Saito M; Aoki J; Najima Y; Kobayashi T; Doki N; Sakamaki H; Ohashi K
Br J Haematol; 2015 Jun; 169(5):756-9. PubMed ID: 25522128
[No Abstract] [Full Text] [Related]
8. CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin.
Herrmann H; Cerny-Reiterer S; Gleixner KV; Blatt K; Herndlhofer S; Rabitsch W; Jäger E; Mitterbauer-Hohendanner G; Streubel B; Selzer E; Schwarzinger I; Sperr WR; Valent P
Haematologica; 2012 Feb; 97(2):219-26. PubMed ID: 21993666
[TBL] [Abstract][Full Text] [Related]
9. Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia.
Parigger J; Zwaan CM; Reinhardt D; Kaspers GJ
Expert Rev Anticancer Ther; 2016; 16(2):137-46. PubMed ID: 26646091
[TBL] [Abstract][Full Text] [Related]
10. Treatment of relapsed acute promyelocytic leukemia with gemtuzumab ozogamicin and all-trans retinoic acid.
Tageja N; Valent J; Zonder J
J Chemother; 2009 Dec; 21(6):705-6. PubMed ID: 20071299
[No Abstract] [Full Text] [Related]
11. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.
Stadtmauer EA
Clin Lymphoma; 2002 Mar; 2 Suppl 1():S24-8. PubMed ID: 11970767
[TBL] [Abstract][Full Text] [Related]
12. Why is it so difficult to use gemtuzumab ozogamicin?
Sylvie Castaigne
Blood; 2013 Jun; 121(24):4813-4. PubMed ID: 23766456
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment with low-dose gemtuzumab ozogamicin in combination chemotherapy followed by stem cell transplantation for children with refractory acute myeloid leukaemia.
Yoshida N; Sakaguchi H; Matsumoto K; Kato K
Br J Haematol; 2012 Sep; 158(5):666-8. PubMed ID: 22712614
[No Abstract] [Full Text] [Related]
14. Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts.
Vasu S; He S; Cheney C; Gopalakrishnan B; Mani R; Lozanski G; Mo X; Groh V; Whitman SP; Konopitzky R; Kössl C; Bucci D; Lucas DM; Yu J; Caligiuri MA; Blum W; Adam PJ; Borges E; Rueter B; Heider KH; Marcucci G; Muthusamy N
Blood; 2016 Jun; 127(23):2879-89. PubMed ID: 27013443
[TBL] [Abstract][Full Text] [Related]
15. Combined treatment with low concentrations of decitabine and SAHA causes cell death in leukemic cell lines but not in normal peripheral blood lymphocytes.
Brodská B; Holoubek A; Otevřelová P; Kuželová K
Biomed Res Int; 2013; 2013():659254. PubMed ID: 24000324
[TBL] [Abstract][Full Text] [Related]
16. Gemtuzumab ozogamicin, mitoxantrone, and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy.
Boyiadzis M; Redner RL; Raptis A; Hou JZ; Agha M; Foon KA
Ann Hematol; 2011 Jun; 90(6):733-5. PubMed ID: 20857113
[No Abstract] [Full Text] [Related]
17. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.
Cooper TM; Franklin J; Gerbing RB; Alonzo TA; Hurwitz C; Raimondi SC; Hirsch B; Smith FO; Mathew P; Arceci RJ; Feusner J; Iannone R; Lavey RS; Meshinchi S; Gamis A
Cancer; 2012 Feb; 118(3):761-9. PubMed ID: 21766293
[TBL] [Abstract][Full Text] [Related]
18. Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy.
Erba HP
Leuk Res; 2015 Feb; 39(2):183-91. PubMed ID: 25577399
[TBL] [Abstract][Full Text] [Related]
19. Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials.
Li X; Xu SN; Qin DB; Tan Y; Gong Q; Chen JP
Ann Oncol; 2014 Feb; 25(2):455-61. PubMed ID: 24478322
[TBL] [Abstract][Full Text] [Related]
20. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]